youtube_live
Q3 2026 earnings • released • EPS beat +257.92% • Revenue miss -15.09%
See resultschevron_right
GRAL:NASDAQ
Grail Inc
$121.44
arrow_upward
+1.94%(+2.32) 1D
Nov 6, 12:33:20 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRAL...
Open
$122.00
High
$129.70
Low
$117.00
Mkt. cap
5.41B
Avg. vol.
1.07M
Volume
402.10K
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
Open
$122.00
High
$129.70
Low
$117.00
Mkt. cap
5.41B
Avg. vol.
1.07M
Volume
402.10K
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
News stories
From web sources and news partners
kalkine.ca
·
23 hours ago
What Could an FDA Panel Vote Mean for GRAIL (NASDAQ:GRAL) as Its Loss Reaches USD 103.6 Million?
The Globe and Mail
·
1 day ago
GRAIL (GRAL) Q3 2026 Earnings Call Transcript
Yahoo Finance Singapore
·
1 day ago
Is GRAIL (GRAL) Fully Valued As Fresh Earnings Reignite Questions Over Galleri?
Profile
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021, GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023, EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.
Joshua Ofman is CEO. Wikipedia
About Grail Inc
CEO-
Employees910
Founded2015
HeadquartersMenlo Park, California, United States
SectorHealth Care
IndustryBiotechnology
Websitegrail.com
Analyst ratings
Based on 10 analysts giving stock ratings to GRAL in the past 3 months
Buy
Buy
5
Hold
5
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for GRAL in the last 3 months.
Highest
Current $121.44
$175.00 (+44.10%)
Average
$131.90 (+8.61%)
Lowest
$74.00 (-39.07%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Bradley Bowers Mizuho Securities | Hold | Maintained | $110.00 | -9.4% | 11/06/2026 |
Kyle Mikson CFA Canaccord Genuity | Buy | Maintained | $150.00 | +23.5% | 11/05/2026 |
David Westenberg Piper Sandler | Hold | Maintained | $74.00 | -39.1% | 11/05/2026 |
Daniel Brennan TD Cowen | Buy | Maintained | $175.00 | +44.1% | 11/05/2026 |
Evie Koslosky Goldman Sachs | Hold | Maintained | $110.00 | -9.4% | 11/05/2026 |
Dan Leonard RBC Capital | Hold | Reiterated | $100.00 | -17.7% | 11/04/2026 |
Robert Bamberger Robert W. Baird | Buy | Maintained | $150.00 | +23.5% | 11/05/2026 |
Kallum Titchmarsh Morgan Stanley | Hold | Maintained | $120.00 | -1.2% | 10/13/2026 |
Doug Schenkel UBS | Buy | Reiterated | $175.00 | +44.1% | 10/02/2026 |
Subbu Nambi Guggenheim | Buy | Maintained | $155.00 | +27.6% | 10/01/2026 |
Unknown Analyst UBS | Buy | Initiated | $105.00 | -13.5% | 09/13/2026 |
Paige Chamberlain Wolfe Research | Hold | Initiated | - | - | 06/01/2026 |
Unknown Analyst Wolfe Research | Hold | Initiated | - | - | 06/01/2026 |
Catherine Ramsey Schulte Robert W. Baird | Buy | Maintained | $70.00 | -42.4% | 05/06/2026 |
Last report
Nov 4, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$3.00 / -$1.90
+257.92%beat
arrow_upward
Revenue / Est. (USD)
37.54M / 44.21M
-15.09%miss
arrow_downward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 43.60M | 40.78M | 44.69M | 37.54M |
Cost of goods sold | 21.26M | 21.62M | 23.78M | 22.17M |
Cost of revenue | 21.26M | 21.62M | 23.78M | 22.17M |
Research and development expenses | 46.90M | 48.02M | 47.43M | 44.07M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 66.38M | 73.44M | 88.36M | 82.44M |
Operating expense | 146.75M | 154.93M | 169.27M | 159.98M |
Total operating expenses | 168.01M | 176.55M | 193.05M | 182.15M |
Operating income | -124.41M | -135.76M | -148.36M | -144.62M |
Other non operating income | -993.00K | - | - | -545.00K |
EBT including unusual items | -116.52M | -127.52M | -166.71M | -137.32M |
EBT excluding unusual items | -116.52M | -127.52M | -141.28M | -137.32M |
Income tax expense | -17.34M | -34.34M | -56.46M | -33.75M |
Effective tax rate | 14.88% | 26.93% | 33.87% | 24.58% |
Other operating expenses | - | - | - | - |
Net income | -99.18M | -93.19M | -110.25M | -103.57M |
Net profit margin | -227.48% | -228.48% | -246.71% | -275.92% |
Earnings per share | -2.44 | -1.37 | -1.34 | 3.00 |
Interest and investment income | 7.96M | 7.99M | 7.23M | 7.84M |
Interest expense | - | - | - | - |
Net interest expenses | 7.96M | 7.99M | 7.23M | 7.84M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -85.50M | -96.97M | -109.67M | -105.93M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events